secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0000950170-23-003436
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics reports FY2022 net loss of $650.2M; exa-cel regulatory submissions complete in Europe
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.
- R&D expenses for FY2022 were $461.6M, up from $340.6M in FY2021, driven by pipeline advancement.
- Net loss for FY2022 was $650.2M, compared to net income of $377.7M in FY2021, due to lower collaboration revenue.
- Regulatory submissions for exa-cel (CTX001) completed in Europe; U.S. BLA rolling submission on track for Q1 2023.
- Enrolling and dosing ongoing for CTX110 (CD19+ B-cell malignancies) and CTX130 (CD70+ T cell lymphomas); next-gen CAR T trials initiating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/0000950170-23-003436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/crsp-20230221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer